


## Interferon-gamma drives brain pathology in a mouse model of multiple system atrophy

February 12 2024, by Jeff Hansen



Multiple system atrophy is a rare and fatal neurodegenerative disease, with no known disease modifying therapy. Credit: University of Alabama at Birmingham



Multiple system atrophy is a rare and fatal neurodegenerative disease, where insoluble inclusions of the protein alpha-synuclein appear in oligodendrocyte cells of the brain. The resulting pathogenesis features neuroinflammation, demyelination and neurodegeneration. Oligodendrocytes produce myelin, an insulating sheath on the axons of nerves.

In 2020, Ashley Harms, Ph.D., and University of Alabama at Birmingham colleagues published an *Acta Neuropathologica* study that used a mouse model to show that the alpha-synuclein pathology from overexpression of alpha-synuclein in oligodendrocytes induced changes that included infiltration of CD4<sup>+</sup> and CD8<sup>+</sup> T cells into the brain, as is seen in human post-mortem brains.

The UAB researchers also showed that mice that were genetically deficient in CD4<sup>+</sup> T cells had attenuated infiltration of peripheral immune cells and attenuated demyelination in the mouse model. In mice with an intact immune system, alpha-synuclein overexpression in the mouse model resulted in increased numbers of CD4<sup>+</sup> T-cells that were also positive for the transcription factor T-bet, along with significant production of the proinflammatory cytokine interferon-gamma, or IFNγ.

Now in a <u>study</u> published in *Acta Neuropathologica Communications*, Harms and colleagues used the mouse model and genetic and pharmacological approaches to show that IFN $\gamma$  is produced primarily by infiltrating CD4<sup>+</sup> T-cells and that IFN $\gamma$  mediates the mechanisms that drive multiple system atrophy.

"These results indicate that IFN $\gamma$  represents a potential future disease-modifying therapeutic target in multiple system atrophy," said Harms, an associate professor in the UAB Department of Neurology. "Future studies are needed to determine the timing and duration of treatment, but these results are promising."



Multiple system atrophy currently has no known disease-modifying therapy.

The mouse model uses an engineered virus that produces overexpression of human alpha-synuclein in oligodendrocytes.

Using mice in which the required transcription factor for IFN $\gamma$  in Th1 helper T cells, Tbet, has been deleted, the UAB researchers showed that absence of Tbet in the mouse model of multiple system atrophy resulted in attenuated neuroinflammation, demyelination and neurodegeneration.

However, it was still not clear that IFN $\gamma$  was the driver of that pathology, because Tbet mediates other pathways besides IFN $\gamma$ .

To specifically determine the role of IFN $\gamma$  in the mouse model, the researchers gave the mice IFN $\gamma$ -neutralizing antibody treatment both before and during overexpression of alpha-synuclein. They found that the antibody treatment attenuated neuroinflammation and the entry of CD4<sup>+</sup> and CD8<sup>+</sup> T cells into the brain, and it reduced demyelination.

A clever genetic trick—a Thy1.1 reporter mouse—was used to show that most of the IFN $\gamma$  in the mouse model of multiple system atrophy is produced by CD4<sup>+</sup> T cells, rather than other resident or infiltrating immune cells. In this reporter mouse, the gene for Thy1.1 is inserted into the promoter of the IFN $\gamma$  gene, so that Thy1.1 is co-expressed in any cell that produces IFN $\gamma$ . Thy1.1 is a cell surface protein, which means that IFN-producing cells can be identified by the presence of Thy1.1.

After alpha-synuclein was overexpressed in the reporter mouse, the researchers removed brain tissue and used immunohistochemistry to identify immune populations known to produce IFN $\gamma$ —including CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, natural killer cells, astrocytes and microglial cells. They found that the CD4<sup>+</sup> T cells expressed the overwhelming majority



of Thy1.1 on their cell surface in response to the overexpression of alphasynuclein.

"These data suggest that the CD4<sup>+</sup> T cell effector subtype, Th1 cells, are facilitating the disease process via production of IFN $\gamma$ ," Harms said. "Together our results show that other immune cell types like CD8<sup>+</sup> T cells, B cells and <u>natural killer cells</u> do not significantly express IFN $\gamma$  following alpha-synuclein overexpression in oligodendrocytes; but CD4<sup>+</sup> T cells drive multiple system atrophy pathology via IFN $\gamma$  expression."

**More information:** Nicole J. Corbin-Stein et al, IFNγ drives neuroinflammation, demyelination, and neurodegeneration in a mouse model of multiple system atrophy, *Acta Neuropathologica Communications* (2024). DOI: 10.1186/s40478-023-01710-x

## Provided by University of Alabama at Birmingham

Citation: Interferon-gamma drives brain pathology in a mouse model of multiple system atrophy (2024, February 12) retrieved 29 April 2024 from <a href="https://medicalxpress.com/news/2024-02-interferon-gamma-brain-pathology-mouse.html">https://medicalxpress.com/news/2024-02-interferon-gamma-brain-pathology-mouse.html</a>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.